Solomon Moshkevich Sells 3,410 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80. Following the completion of the transaction, the insider directly owned 129,019 shares in the company, valued at $34,264,866.02. This trade represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The shares were sold at an average price of $254.07, for a total transaction of $305,900.28.
• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $263,094.90.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $272.90, for a total value of $818,700.00.
• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $218.43, for a total value of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The shares were sold at an average price of $202.84, for a total value of $335,091.68.

Natera Stock Down 3.4%

Shares of NASDAQ NTRA opened at $265.38 on Friday. The stock has a market cap of $38.01 billion, a PE ratio of -162.81 and a beta of 1.51. Natera, Inc. has a 52-week low of $136.21 and a 52-week high of $288.04. The business has a 50-day moving average price of $252.06 and a 200 day moving average price of $223.09.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.The firm’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.74) earnings per share. Sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NTRA has been the subject of several analyst reports. Robert W. Baird set a $265.00 price target on Natera in a research note on Friday, May 8th. Royal Bank Of Canada initiated coverage on Natera in a research note on Thursday, June 11th. They set an “outperform” rating and a $275.00 price target on the stock. Piper Sandler reissued an “overweight” rating and issued a $249.00 price objective on shares of Natera in a research note on Tuesday, May 12th. Zacks Research cut Natera from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Finally, Guggenheim lifted their price target on shares of Natera from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $267.83.

Institutional Trading of Natera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Reflection Asset Management purchased a new position in shares of Natera during the 4th quarter worth about $29,000. Elevation Wealth Partners LLC acquired a new position in Natera during the second quarter worth approximately $30,000. Palladiem LLC acquired a new position in Natera during the fourth quarter worth approximately $31,000. Horizon Investments LLC purchased a new position in Natera during the third quarter worth approximately $32,000. Finally, International Assets Investment Management LLC boosted its holdings in shares of Natera by 132.9% in the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 97 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera reported second-quarter revenue of $752.8 million, up 37.7% year over year and well above analysts’ $661.2 million estimate. Its adjusted loss of $0.47 per share was also slightly better than the $0.49 consensus and improved from a $0.74 loss a year earlier. Gross margin increased to 64.5% from 63.4%. Natera Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised or reaffirmed full-year 2026 revenue guidance at approximately $2.9 billion, ahead of the roughly $2.8 billion analyst consensus. The outlook reinforces expectations for continued demand across Natera’s reproductive health, oncology, and transplant testing businesses.
• Positive Sentiment: Natera submitted its Signatera molecular residual disease test to Japan’s PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer. Regulatory approval could expand Signatera’s international addressable market and create another source of oncology revenue. Natera Submits Signatera to Japan’s PMDA
• Neutral Sentiment: CEO Steven Leonard Chapman, CFO Michael Burkes Brophy, and other executives sold shares totaling about $2.0 million. The transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding from vested equity awards, and the executives retained substantial holdings, limiting their value as a negative confidence signal.
• Negative Sentiment: Natera remains unprofitable, reporting a negative net margin and return on equity. Although the quarterly loss narrowed year over year, investors may be focused on the company’s path to sustained earnings, particularly after the stock’s sharp rise and proximity to its 52-week high.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.